Sinopharm Group Co (HKSE:01099) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sinopharm Group Co's annualized Gross Profit for the quarter that ended in Dec. 2023 was HK$0 Mil. Sinopharm Group Co's average Total Assets over the quarter that ended in Dec. 2023 was HK$419,349 Mil. Therefore, Sinopharm Group Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Sinopharm Group Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Sinopharm Group Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Gross-Profit-to-Asset % Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

14.70

14.28

13.84

12.95

12.84

Sinopharm Group Co Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															159.84	-	136.15	-	152.59

Competitive Comparison of Sinopharm Group Co's Gross-Profit-to-Asset %

For the Medical Distribution subindustry, Sinopharm Group Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co's Gross-Profit-to-Asset % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Gross-Profit-to-Asset % falls into.

Sinopharm Group Co Gross-Profit-to-Asset % Calculation

Sinopharm Group Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	53061.049	/	( (407349.761	+	419349.185)	/ 2 )
	=	53061.049	/	413349.473
	=	12.84 %

Sinopharm Group Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (0	+	419349.185)	/ 1 )
	=	0	/	419349.185
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sinopharm Group Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co (HKSE:01099) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA X2S:Germany X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (HKSE:01099) Headlines

No Headlines